IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm Everest Group^® has named IQVIA a “front-runner generative AI leader” for the life sciences industry in its recent report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.”

IQVIA was the only clinical research organization to receive the highest ranking of front-runner in the report, which measures the value impact of end-to-end generative AI capabilities for 15 carefully selected broad-based AI companies, CROs and life sciences specialists and niche firms. IQVIA is also the only CRO with a dedicated technology business unit to receive this designation.

“By striving for operational excellence and emphasizing the need for responsible AI governance, IQVIA is taking a thoughtful approach to its generative AI strategy, scaling select use cases from concept to deployment to maximize value across the stages of the product life cycle,” said Aastha Malik, practice director, Everest Group.

The report ranks IQVIA among five front-runners and says it showed industry leadership in its innovative strategic integrations of generative AI capabilities through various stages of research and development that help enable new ways of working. This includes several IQVIA Healthcare-grade AI^® solutions to identify nuances in the patient journey for improved clinical trial design, enhanced product commercialization strategies with deeper provider engagement analytics and precise market access insights.

“Today’s life sciences and healthcare organizations are looking to balance AI innovation with continuous service delivery at high standards, striving for operational excellence,” said Harietta Eleftherochorinou, vice president, AI Strategy and Operations, IQVIA. “The pace of AI advancement is extremely fast, making it important to implement AI with effective governance and drive tangible results while incentivizing for AI experimentation and keeping up to date with emerging AI technologies. With Healthcare-grade AI as our cornerstone for privacy, quality and trust, and building on the insights from over a decade of AI solutions in the market, we are systematic in identifying the areas where AI makes a real difference and moving effectively from AI ideas to operationalization to create real-world value for our customers and their patients.”

IQVIA is gaining recognition for its ability to drive innovation and operational efficiency throughout the R&D life cycle. Earlier this year, IQVIA AI Assistant, an interactive tool to revolutionize insight generation for the healthcare and life sciences industries, was recognized with the PM360 Innovation Award in the AI Category.

About Everest Group

Everest Group is a leading global research firm helping business leaders make confident decisions. It guides clients through today’s market challenges and strengthens their strategies by applying contextualized problem-solving to their unique situations. This drives maximized operational and financial performance and transformative experiences. The Everest Group’s deep expertise and tenacious research focused on technology, business processes and engineering through the lenses of talent, sustainability and sourcing deliver precise and action-oriented guidance. Find further details and in-depth content at www.everestgrp.com.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI^®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.